09:52 AM EDT, 07/30/2025 (MT Newswires) -- NewAmsterdam Pharma ( NAMS ) said Wednesday that an analysis of its late-stage trial data showed its obicetrapib therapy "significantly reduced" biomarkers associated with Alzheimer's disease.

Treatment with a 10 mg daily dose of obicetrapib for 12 months resulted in statistically significant improvements in plasma p-tau217 levels in both the full patient population and among ApoE4 carriers, the company said.

The analysis' results support the case for obicetrapib, a CETP inhibitor, a class of drugs designed to inhibit cholesteryl ester transfer protein, as a potential upstream approach to preventing Alzheimer's disease, the company said.

NewAmsterdam said it plans to discuss the trial results with regulators to determine next steps, the company said.

Shares of the company were up less than 1% in recent Wednesday premarket activity.

Price: 22.99, Change: +0.21, Percent Change: +0.92